Abstract
Although a large number of drugs, chemicals, and endogenous compounds are known as substrates or inhibitors of microsomal cytochrome P450 enzymes, systematic attempts to explore substrate and inhibitor specificity of individual cytochrome P450 species have been occasional. An improved understanding of the specificity of individual cytochrome P450 enzymes, however, is desirable for several reasons. First, animal species differ from each other and from humans with respect to their patterns of cytochrome P450 enzymes involved in detoxication and bioactivation of cytotoxic and genotoxic chemicals. More knowledge of the specificity of these enzymes facilitates the explanation of species differences in metabolism and facilitates the design of chemical toxicity studies. Furthermore, reliable substrate models offer the opportunity to predict whether a drug is likely to be a substrate of a particular cytochrome P450 enzyme and thus whether its plasma concentration and, consequently, its therapeutic effects may be subjected to interindividual variations of the activity of this enzyme. Likewise, more knowledge about structural features of compounds inhibitory for cytochrome P450 enzymes is required, to evaluate whether one drug may be inhibitory for the metabolism of one or more other drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Cohen GM, Mannering GJ (1973) Involvement of a hydrophobic site in the inhibition of the microsomal p-hydroxylation of aniline by alcohols. Mol Pharmacol 9: 383–397
Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/ sparteine metabolism-clinical aspects. Pharmacol Ther 46: 377–394
Ferenzy GG, Morris GM (1989) The active site of cytochrome P-450 nifedipine oxidase: a model-building study. J Mol Graphics 7: 206–211
Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3835
Hansch C (1971) Quantitative structure-activity relationships in drug design. In: Ariens EJ (ed) Drug design, vol 1. Academic, New York, pp 271–342
Hansch C, Clayton JM (1973) Lipophilic character and biological activity of drugs: II. The parabolic case. J Pharm Sci 62: 1–21
Hansch C, Fujita T (1964) pair-analysis. A method for the correlation of biological activity and chemical structure. J Am Chem Soc 86: 1616–1626
Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W (1984) A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. Can J Physiol Pharmacol 62: 860–862
Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isoenzymes of human liver cytochrome P-450. Drug Metab Dispos 13: 443–448
Islam SA, Wolf CR, Lennard MS, Sternberg MJE (1991) A three-dimensional molecular template for substrates of human cytochrome P-450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12: 2211–2219
Jerina DM, Michaud DP, Feldmann RJ, Armstrong RN, Vyas KP, Thakker DR, Yagi H, Thomas PE, Ryan DE, Levin W (1982) Stereochemical modeling of the catalytic site of cytochrome P-450c. In: Sato R, Kato R (eds) Microsomes, drug oxidations, and drug toxicity. Japan Scientific Societies, Tokyo, pp 195–201
Kellis JT, Vickery LE (1987) The active site of aromatase cytochrome P-450. J Biol Chem 262 18: 8840–8844
Kronbach T, Dayer P, Meyer UA (1985) Debrisoquine(D)/sparteine (SP)-type polymorphism in drug oxidation: a model of the active site of the involved cytochrome P-450 isozyme. Experientia 41: 822
Kronbach T, Mathys D, Gut J, Catin T, Meyer UA (1987) High performance liquid chromatographic assays for bufuralol l’-hydroxylase, debrisoquine 4- hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal Biochem 162: 24–32
Kubinyi H (1990) Quantitative structure-activity relationships (QSAR) and molecular modelling in cancer research. J Res Clin Oncol 116: 529–537
Laughton CA, Neidle S (1990) Inhibitors of the P-450 enzymes aromatase and lyase. Crystallographic and molecular modeling studies suggest structural features of pyridylacetic acid derivatives responsible for differences in enzyme inhibitory activity. J Med Chem 33: 3055–3060
Laughton CA, Neidle S, Zvelebil MJJM, Sternberg MJE (1990) A molecular model for the enzyme cytochrome P45017a, a major target for the chemotherapy of prostatic cancer. Biochem Biophys Res Commun 171: 1160–1167
Lewis DFV (1987) Quantitative structure-activity relationships in a series of alcohols exhibiting inhibition of cytochrome P-450 mediated aniline hydroxylation. Chem Biol Interact 62: 271–280
Lewis DFV, Ioannidis C, Parke DV (1987) Structural requirements for substrates of cytochromes P-450 and P-448. Chem Biol Interact 64: 39–60
Lu AYH, West SB (1980) Multiplicity of mammalian microsomal cytochromes P-450. Pharmacol Rev 31: 277–295
Marshall GR (1987) Computer-aided drug design. Annu Rev Pharmacol Toxicol 27: 193–213
Miwa GT, Walsh JS, Lu AYH (1984) Kinetic isotope effects on cytochrome P-450-catalyzed oxidation reactions: the oxidative O-dealkylation of 7- ethoxycoumarin. J Biol Chem 259: 3000–3004
Murray M (1989) Inhibition of drug metabolism by phenothiazine tranquilizers: quantitative structure-activity relationships and selective inhibition of cytochrome P-450 isoform-specific activities. Chem Res Toxicol 2: 240–246
Nelson DR, Strobel HW (1989) Secondary structure prediction of 52 membrane-bound cytochromes P450 shows a strong structural similarity to P450cam. Biochemistry 28: 656–660
Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by P-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80
Poulos TL, Howard A J (1987) Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry 26: 8165–8174
Poulos TL, Finzel BC, Gunsalus IC, Wagner GC, Kraut JJ (1985) The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. J Biol Chem 260: 16122–16130
Poulos TL, Finzel BC, Howard AJ (1986) Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. Biochemistry 25: 5314–5322
Poulos TL, Finzel BC, Howard AJ (1987) High-resolution crystal structure of cytochrome P450cam. J Mol Biol 195: 687–700
Sabljic A, Protic-Sabljic M (1983) Quantitative structure-activity study on the mechanism of inhibition of microsomal p-hydroxylation of aniline by alcohols. Mol Pharmacol 23: 213–218
Schwarze W, Jaeger J, Janig GR, Ruckpaul K (1988) Active site model of cytochrome P-450 LM2. Biochem Biophys Res Commun 150: 996–1005
Strobl GR, Wolff T (1992a) Structural models for inhibitors and substrates of cytochrome P-450 2D6 based on molecular modeling analysis. In: Archakov AI, Bachmanova (eds) Cytochrome P-450: structure and function, biotechnological and ecological aspects. INCO-TNC, Moscow, Russia, 1992, pp 736–738
Strobl GR, von Kruedener S, Stoeckigt J, Guengerich FP, Wolff T (1992b) Development of a pharmacophor for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 1993 (in press)
Testa B (1981) Structural and electronic factors influencing the inhibition of aniline hydroxylation by alcohols and their binding to cytochrome P-450. Chem Biol Interact 34: 287–300
Tullman RH, Walsh JS, Miwa GT (1984) The stereochemistry of P-450 and P-448 catalyzed O-dealkylation of 7-ethoxycoumarin. Fed Proc 43: 346
Verloop A, Hoogenstraaten W, Tipker J (1976) Development and applications of new steric substituent parameters in drug design. In: Ariens EJ (ed) Drug design, vol 7. Academic, New York, pp 165–207
Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45: 2116–2122
Wolff T, Wanders H, Guengerich FP (1989) Organic solvents as modifiers of aldrin epoxidase in reconstituted monooxygenase systems and in microsomes. Biochem Pharmacol 38: 4217–4223
Wrighton SA, Thomas PE, Ryan DE, Levin W (1987) Purification and characterization of ethanol-inducible human hepatic cytochrome P-450 HLj. Arch Biochem Biophys 258: 292–297
Yagi H, Jerina DM (1982) Absolute configuration of the trans-9, 10-dihydrodiol metabolite of the carcinogen benzo[a]pyrene. J Am Chem Soc 104: 4026–4027
Yang SK, Mushtaq M, Chiu, PL (1985) Stereoselective metabolism and activation of polycyclic aromatic hydrocarbons. In: Harvey RG (ed) Polycyclic hydrocarbons and carcinogens. American Chemical Society, Washington, pp 19–34 (Series No 283 )
Zvelebil MJJM, Wolf CR, Sternberg MJE (1991) A predicted three-dimensional structure of human cytochrome P450: implications for substrate specificity. Protein Eng 4: 271–282
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wolff, T., Strobl, G., Greim, H. (1993). Structural Models for Substrates and Inhibitors of Cytochrome P450 Enzymes. In: Schenkman, J.B., Greim, H. (eds) Cytochrome P450. Handbook of Experimental Pharmacology, vol 105. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77763-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-77763-9_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77765-3
Online ISBN: 978-3-642-77763-9
eBook Packages: Springer Book Archive